Metacrine IncOOTC MTCR Stock Report

Metacrine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapies for patients with liver and gastrointestinal (GI) diseases. The company is headquartered in San Diego, California and currently employs 10 full-time employees. The company went IPO on 2020-09-16. The firm is focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal (GI) diseases. The firm's program targets the farnesoid X receptor (FXR), which is central to modulating liver and GI diseases. The firm's product candidates include MET409 and MET642. The firm is developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease characterized by excess liver fat, inflammation and fibrosis. The firm is focused on the farnesoid X receptor (FXR), which is central to modulating gastrointestinal (GI) and liver diseases. The firm is pursuing the development of MET642 for the treatment of Ulcerative Colitis (UC). Its Inflammatory Bowel Disease (IBD) is a global health issue and is thought to occur due to a maladaptive immune response to gut microbes. UC and Crohn’s disease are the two primary types of IBD.